David B Volkin

Dr. Volkin is the Ronald T. Borchardt Distinguished Professor of Pharmaceutical Chemistry, and Head, Macromolecule and Vaccine Stabilization Center (MVSC) at The University of Kansas. He earned a BA in Chemistry at the University of California, San Diego (Revelle College) and a PhD in Biochemical Engineering at the Massachusetts Institute of Technology. He joined the KU faculty in 2010, after a 20-year career in the vaccine and biopharmaceutical industry, including senior director positions at Merck Research Laboratories (Merck) and Centocor R&D (J&J). He led groups responsible for analytical and formulation development of vaccines and therapeutic protein drugs. He has contributed to bringing dozens of candidates into human clinical trials, including five vaccines and three monoclonal antibody drugs now approved for commercial use. He is co-author of ~135 scientific publications and co-inventor on 15 U.S. patents, including the stabilization and formulation of the commercial human papillomavirus (Gardasil®) and rotavirus (RotaTeq®) vaccines. He was awarded the American Association of Pharmaceutical Scientists (AAPS) Research Achievement Award in Biotechnology in 2015.